Amarin | AMRN - Despesas De Vendas E Administração

Preço das Ações
14.31
Mudança Diária
-0.28 -1.92%
Mensal
-2.52%
Anual
37.20%
Q2 Previsão
13.88




Despesas De Vendas E Administração Alterar Data
AbbVie USD 3.89B 325M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 18.97M 1.03M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
DBV Technologies USD 3.63M 3.18M 2025-09
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12